CD8A and neoplasm: A phase 2 single-arm trial evaluating the efficacy of G47∆ observed specific antitumor immune responses, such as an increased tumor-infiltrating CD4+ and CD8+ lymphocyte populations after intratumoral administration of G47∆ in glioma patients [289].